Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences and Arcus Biosciences are conducting a Phase 3 clinical study titled A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations. The study aims to compare the effectiveness of zimberelimab and domvanalimab combined with chemotherapy against pembrolizumab with chemotherapy in improving overall survival in patients with untreated metastatic non-small cell lung cancer.
The interventions being tested include zimberelimab and domvanalimab, both administered intravenously, in combination with chemotherapy drugs such as carboplatin, cisplatin, paclitaxel, nab-paclitaxel, and pemetrexed. These treatments are intended to improve survival rates in patients without specific genomic tumor aberrations.
The study is designed as a randomized, open-label trial with a parallel intervention model. There is no masking involved, and the primary purpose is treatment-focused. Participants are allocated randomly to receive either the experimental combination of zimberelimab and domvanalimab with chemotherapy or the active comparator, pembrolizumab with chemotherapy.
The study began on October 12, 2022, and is currently recruiting participants. The primary completion and estimated study completion dates are not specified, but the last update was submitted on July 21, 2025. These dates are crucial for tracking the study’s progress and anticipated outcomes.
This study could significantly impact the stock performance of Gilead Sciences and Arcus Biosciences, as positive results may enhance investor confidence and market position. The study’s outcomes could also influence competitive dynamics in the oncology sector, particularly regarding treatments for non-small cell lung cancer.
The study is ongoing, with further details available on the ClinicalTrials portal.